We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+47.67%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$62.8M
Cap. Flow
-$30.5M
Cap. Flow %
-7.81%
Top 10 Hldgs %
31.01%
Holding
170
New
75
Increased
15
Reduced
22
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.07M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$5.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.07M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.5M
2
LLY icon
Eli Lilly
LLY
+$11M
3
TGTX icon
TG Therapeutics
TGTX
+$10.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.76M
5
SLNO
Soleno Therapeutics
SLNO
+$7.92M

Sector Composition

Rank Sector Weight
1 Miscellaneous 63.28%
2 Healthcare 36.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
126
PMV Pharmaceuticals
PMVP
$80.2M
$15.8K ﹤0.01%
+11,300
New +$15.6K
APLT
127
CALL
DELISTED
Applied Therapeutics
APLT
$11.5K ﹤0.01%
+19,000
New +$8.95K
AUPH icon
128
PUT
Aurinia Pharmaceuticals
AUPH
$2.25B
$7.74K ﹤0.01%
+700
New +$7.65K
TVTX icon
129
PUT
Travere Therapeutics
TVTX
$5.92B
$7.17K ﹤0.01%
+300
New +$5.64K
JBIO
130
PUT
Jade Biosciences
JBIO
$1.08B
$2.77K ﹤0.01%
+1,046
New +$8.55K
ALT icon
131
PUT
Altimmune
ALT
$632M
– –
-171,400
Closed -$663K
AMGN icon
132
Amgen
AMGN
$208B
– –
-52,100
Closed -$14.5M
AMGN icon
133
PUT
Amgen
AMGN
$208B
– –
-62,100
Closed -$17.3M
ARGX icon
134
argenx
ARGX
$62B
– –
-5,974
Closed -$3.29M
ARVN icon
135
Arvinas
ARVN
$542M
– –
-96,455
Closed -$710K
BHVN icon
136
CALL
Biohaven
BHVN
$2.06B
– –
-100,000
Closed -$1.41M
BMEA icon
137
CALL
Biomea Fusion
BMEA
$133M
– –
-568,900
Closed -$1.02M
CAPR icon
138
PUT
Capricor Therapeutics
CAPR
$527M
– –
-106,600
Closed -$1.06M
COGT icon
139
PUT
Cogent Biosciences
COGT
$5.47B
– –
-201,400
Closed -$1.45M
CRDF icon
140
CALL
Cardiff Oncology
CRDF
$107M
– –
-208,100
Closed -$656K
ELDN icon
141
Eledon Pharmaceuticals
ELDN
$213M
– –
-64,613
Closed -$175K
ELEV
142
DELISTED
Elevation Oncology
ELEV
– –
-362,935
Closed -$133K
ETNB
143
DELISTED
89bio
ETNB
– –
-98,382
Closed -$966K
GILD icon
144
Gilead Sciences
GILD
$186B
– –
-30,000
Closed -$3.33M
ITOS
145
DELISTED
iTeos Therapeutics
ITOS
– –
-206,200
Closed -$2.06M
LLY icon
146
CALL
Eli Lilly
LLY
$1.03T
– –
-10,000
Closed -$7.8M
LLY icon
147
Eli Lilly
LLY
$1.03T
– –
-14,816
Closed -$11M
MLTX icon
148
PUT
MoonLake Immunotherapeutics
MLTX
$1.05B
– –
-41,300
Closed -$1.95M
MRK icon
149
Merck
MRK
$362B
– –
-20,000
Closed -$1.58M
NKTR icon
150
CALL
Nektar Therapeutics
NKTR
$2.29B
– –
-47,474
Closed -$85.9K
3 4 5
6
7

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Diadema Partners held 170 positions worth $391M, up 19% from $328M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Diadema Partners withdrew a net $30.5M in Q3 2025, closing 40 positions and reducing 22 holdings. Its most notable exit was Amgen, an estimated $14.5M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 63% of assets, up from 51% a quarter earlier, followed by Healthcare.

Against the trend, Diadema Partners opened a new position in Bristol-Myers Squibb worth $5.86M.

  • Diadema Partners's largest Q3 2025 buy was Bristol-Myers Squibb: 130,000 shares worth $5.86M.
  • Diadema Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $13.9M increase.
  • Diadema Partners's biggest Q3 2025 reduction was TG Therapeutics, cutting an estimated $10.2M.
  • Diadema Partners fully exited Amgen in Q3 2025, selling an estimated $14.5M.
  • Diadema Partners's ten largest holdings make up 31% of its $391M portfolio in Q3 2025.
  • Diadema Partners opened 75 new positions and closed 40 in Q3 2025.
  • Diadema Partners's portfolio value rose 19% quarter-over-quarter to $391M.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.